Lawsuits alleging injuries caused by the type 2 diabetes drug Invokana are mounting across the country, but legal experts say they expect a large portion of them to come to Philadelphia because it is the home state of one of the manufacturers. At least 15 lawsuits have been filed in the Philadelphia Court of Common Please since December, court records show.
The lawsuits blame Johnson & Johnson’s Janssen Pharmaceuticals and Mitsubishi Tanabe Pharmaceuticals for failing to warn the public of possible risks with Invokana. The lawsuits also claim that the medication is defectively designed because it does not allow the body to metabolize excess glucose, instead directing it to be excreted through the kidneys. This, the plaintiffs claim, can lead to kidney failure and ketoacidosis, a serious condition in which too much acid builds up in the blood.
More than 150 Invokana lawsuits have been filed in state courts in Missouri and Illinois. Several others have been filed in federal court, including New Jersey. But at least a thousand other lawsuits are expected to be filed.
Legal experts say that they expect the litigation to reach mass tort and federal multidistrict litigation status.
The boom in Invokana lawsuits beginning in December coincides with a Food and Drug Administration (FDA) Safety Alert in which the agency announced it was requiring the manufacturers add new warnings on the drugs’ safety label to include an increased risk of ketoacidosis. The FDA also ordered the companies to conduct post-market studies on Invokana side effects.
Invokana was approved by the FDA in 2013 for the treatment of type 2 diabetes. Since then, it has generated more than $1 billion in sales.
Source: The Legal Intelligencer